Independent pricing breakdown of Ro's telehealth services including GLP-1 weight loss, erectile dysfunction, hair loss, and mental health programs. Covers total cost, hidden fees, and how Ro compares to competitors.
Independent analysis of who benefits most from Sequence, now operating as WeightWatchers Clinic. Covers ideal patient criteria, GLP-1 prescribing, cost, clinical evidence, and how it compares to alternatives.
Independent comparison of Shed and its top alternatives for compounded GLP-1 weight loss, telehealth convenience, cost, and clinical support. Evidence-based analysis with cited sources.
An independent comparison of Strut Health alternatives for men's hair loss, ED, and peptides. Evidence-based picks with pricing, prescribing details, and clinical backing.
A clinical comparison of Talkspace and its top alternatives for therapy, psychiatry, couples counseling, and medication management, with evidence-based recommendations for each use case.
An independent clinical review of Thirty Madison's prescription and intake process across Keeps, Cove, Picnic, and Facet. Covers medications prescribed, provider qualifications, cost breakdown, and how the platform compares to alternatives.
An independent clinical assessment of Thorne supplements, covering prescription gaps, evidence limitations, cost considerations, and what this premium brand cannot replace.
Independent comparison of Transcend alternatives for testosterone therapy, peptides, thyroid support, and women's HRT. Evidence-based analysis with cost breakdowns and clinical guidance.
An independent breakdown of the TrimRx prescription and intake process for compounded GLP-1 medications, including cost, clinical evidence, safety considerations, and how it compares to alternatives.
Independent pricing breakdown of TrimRx compounded GLP-1 programs. We analyze monthly costs, hidden fees, what's included, and how TrimRx stacks up against Hims, Henry Meds, and other telehealth weight-loss platforms.
Independent pricing analysis of Truepill's B2B pharmacy infrastructure, consumer-facing costs, regulatory history, and how it compares to alternative telehealth pharmacy platforms.
An independent analysis of Truepill's B2B telehealth pharmacy infrastructure, who benefits most from platforms built on it, and the clinical and regulatory factors patients should weigh.
Independent cost breakdown of Viome's microbiome testing kits and subscription supplements, with clinical evidence on whether the science justifies the price.
Vyleesi runs $850 to $950 per carton (about $215-$240 per dose), versus $800-$1,000 for brand Addyi or $30-$80 for generic flibanserin.
Crestor can raise transaminases and rarely cause serious injury. Learn what the current rosuvastatin label says and how clinicians read the full liver pattern.
Lipitor can raise liver enzymes and very rarely cause serious injury. See the current atorvastatin label, dose signal, symptom pattern, and monitoring logic.
Combining Eliquis (apixaban) with ibuprofen raises bleeding risk significantly. Learn why this interaction matters, what the evidence shows, and which pain relievers are safer alternatives.
Find out if Blue Cross Blue Shield covers Eliquis (apixaban), including formulary tiers, copay ranges, prior authorization requirements, and how to lower your out-of-pocket cost.
Learn whether Kaiser Permanente covers Eliquis (apixaban), what tier it falls under, prior authorization requirements, copay costs, and how to get coverage approved.
Hair loss has been reported with metoprolol. Understand the evidence, other causes of shedding, formulation questions and how to discuss a treatment change.
A source-by-source audit of Sylvester Stallone's public testosterone and HGH record—and the doses, diagnosis, current use, and physique claims it cannot establish.
Evidence-based guide to safely discontinuing tadalafil (Cialis) for ED or BPH, including tapering considerations, rebound risks, and when to consult your prescriber.
A guide to tadalafil food and supplement interactions, including grapefruit, alcohol, nitrates, and common supplements that alter PDE5 inhibitor pharmacokinetics.
Evidence-based monitoring guide for tadalafil (Cialis) use in adults 65 and older, covering renal function, blood pressure, drug interactions, falls risk, and deprescribing timelines.
A clinical overview of tadalafil manufacturing origins, generic entry, FDA shortage events, and current supply chain status for Cialis and its generic equivalents.
A guide to tadalafil (Cialis) overdose management, including symptoms, treatment protocols, pharmacokinetics at supratherapeutic doses, and when to seek emergency care.
A physician-level breakdown of how CJC-1295 (modified GRF 1-29) activates GHRH receptors, amplifies pulsatile GH release, and sustains IGF-1 elevation for up to 8 days through Drug Affinity Complex albumin binding.
A clinician-grade monitoring schedule for CJC-1295 (modified GRF 1-29), covering baseline labs, follow-up intervals, IGF-1 targets, safety markers, and when to adjust or discontinue therapy.
How pharmacogenomics and genetic variants in GHRHR, GH1, IGF1, and SOCS genes shape individual responses to CJC-1295 modified GRF. Evidence-based guide for clinicians and patients.
Clinical monograph covering the 5-α reductase inhibitor drug class, including finasteride and dutasteride. Mechanism, pharmacokinetics, landmark trials, dosing, adverse effects, and prescribing considerations for BPH and androgenetic alopecia.
Clinical monograph covering the aromatase inhibitor drug class: anastrozole, letrozole, and exemestane. Mechanism, dosing, trials, adverse effects, monitoring, and off-label use in men.
A prescriber-level monitoring guide for biguanides (metformin). Covers baseline labs, renal surveillance, vitamin B12 screening, lactic acidosis risk stratification, and contrast-hold protocols.
A prescriber-level monograph covering bisphosphonate pharmacology, dosing, efficacy data, adverse effects, monitoring, and clinical decision points for osteoporosis management.
A prescriber-level guide to bisphosphonate monitoring, covering baseline labs, on-treatment surveillance, renal function tracking, dental screening, and when to consider a drug holiday.
A clinician-focused summary of bisphosphonate prescribing in special populations including renal impairment, geriatric patients, premenopausal women, pediatric use, and pregnancy. Includes dose adjustments, monitoring, and contraindications.
Complete drug-drug interaction (DDI) table for the copper peptides class, centered on GHK-Cu. Covers topical and systemic formulations, chelation conflicts, retinoid co-use, and monitoring guidance for polypharmacy patients.
Evidence-based monitoring protocol for copper peptide (GHK-Cu) therapy covering baseline labs, ongoing surveillance intervals, serum copper and ceruloplasmin targets, hepatic panels, and discontinuation criteria for prescribing clinicians.
Evidence-based protocols for identifying, grading, and managing adverse events associated with DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) in type 2 diabetes.
A clinician-level monograph covering the DPP-4 inhibitor drug class: mechanism, pharmacokinetics, CV outcomes trials, renal dosing, place in therapy, and prescribing guidance for sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin.
A prescriber-level guide to the monitoring bundle for DPP-4 inhibitors (gliptins), covering baseline labs, follow-up intervals, renal dose adjustments, and safety surveillance for sitagliptin, saxagliptin, linagliptin, and alogliptin.
A clinician-focused drug-drug interaction reference for systemic estrogens, covering CYP3A4 inducers, thyroid binding changes, anticoagulant effects, and management strategies for estradiol, conjugated estrogens, and ethinyl estradiol.
Evidence-based titration and tapering protocols for systemic estrogen therapy in menopausal hormone replacement, including oral estradiol, transdermal patches, and conjugated estrogens. Written for prescribers and dispensing pharmacists.
A prescriber-level guide to billing codes, payer policies, prior-authorization workflows, and appeals strategies for GHRH analog peptides including sermorelin, tesamorelin, and CJC-1295.
Evidence-based prescribing guide for tirzepatide and other GIP/GLP-1 dual agonists in renal impairment, hepatic disease, older adults, adolescents, pregnancy, and heart failure with preserved ejection fraction.
Clinician-focused review of prescribing triple agonists like retatrutide in special populations including renal impairment, hepatic disease, older adults, pregnancy, and adolescents.
A prescriber-level monograph covering GLP-1 receptor agonist pharmacology, approved indications, landmark trial data, dosing, adverse effects, and clinical selection guidance.
Clinician-focused drug-drug interaction reference for GLP-1 receptor agonists including semaglutide, liraglutide, dulaglutide, tirzepatide, and exenatide. Covers gastroparesis-mediated absorption changes, hypoglycemia stacking, warfarin monitoring, and oral contraceptive efficacy.
Complete drug-drug interaction (DDI) reference for growth hormone secretagogues including ipamorelin, CJC-1295, tesamorelin, sermorelin, and MK-677. Written for prescribers and pharmacists.
Evidence-based adverse-event management protocols for BPC-157 and TB-500 healing peptides, including grading scales, clinical decision points, dose modifications, and when to discontinue therapy.
Clinician-focused drug-drug interaction reference for BPC-157 and TB-500 healing peptides, covering known pharmacologic interactions, CYP considerations, and co-prescribing precautions.
Evidence-based special-populations guide for BPC-157 and TB-500 (thymosin beta-4). Covers renal impairment, hepatic dysfunction, pediatrics, geriatrics, pregnancy, lactation, and immunocompromised patients at MD/PharmD level.
Complete drug-drug interaction table for meglitinides (repaglinide, nateglinide) covering CYP2C8, CYP3A4, CYP2C9, and OATP1B1 interactions with clinical management recommendations.
A clinician-focused comparison of repaglinide vs nateglinide covering pharmacokinetics, efficacy, renal dosing, drug interactions, and evidence-based selection criteria for prandial glucose control.
Clinical monograph covering the NAD precursor drug class, including nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin, and nicotinamide. Mechanisms, pharmacokinetics, trial data, dosing, safety, and prescribing considerations.
A prescriber-level monitoring bundle for NAD precursor therapy (NMN, NR, niacin, niacinamide) covering baseline labs, follow-up intervals, safety signals, and dose-adjustment triggers.
A clinician-facing guide to billing codes, prior-authorization workflows, and payer strategies for PDE5 inhibitors including sildenafil, tadalafil, vardenafil, and avanafil.
Complete drug-drug interaction (DDI) reference for PDE5 inhibitors including sildenafil, tadalafil, vardenafil, and avanafil. CYP3A4 interactions, nitrate contraindications, alpha-blocker timing, and dose adjustments for prescribers.
Evidence-based monitoring protocol for micronized progesterone and synthetic progestins in menopausal HRT and luteal support, including lab panels, imaging schedules, and safety checkpoints.
Evidence-based guide for clinicians on selecting between micronized progesterone and synthetic progestins for menopausal HRT, luteal support, and endometrial protection. Covers pharmacology, trial data, breast risk, and patient-specific decision points.
A prescriber-level guide to monitoring selective estrogen receptor modulators (SERMs) including enclomiphene, tamoxifen, raloxifene, and clomiphene. Covers baseline labs, on-therapy surveillance, imaging intervals, and discontinuation protocols.